PharmAbcine Inc. announced that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co. Inc., Rahway, NJ., USA), to initiate a Phase I combination trial of PMC-309, a novel anti-VISTA (V-domain Ig suppressor of T cell activation) antibody, in combination with KEYTRUDA(R) (pembrolizumab), MSD's anti-PD-1 therapy. Under the terms of the agreement, PharmAbcine will sponsor a Phase I study in Australia to evaluate the safety and clinical efficacy of the combination therapy for the treatment of multiple advanced solid tumors, and MSD will supply KEYTRUDA.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,915 KRW | -8.91% | -.--% | -22.27% |
1st Jan change | Capi. | |
---|---|---|
-22.27% | 64.47M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.31% | 16.5B | |
+2.44% | 13.39B | |
+27.89% | 11.1B |
- Stock Market
- Equities
- A208340 Stock
- News PharmAbcine Inc.
- Pharmabcine Announces Collaboration Agreement with MSD to Evaluate Anti-Vista Antibody PMC-309 in Combination with Keytruda(R) (Pembrolizumab)